ATE219061T1 - Huperzin a analoge verbindungen - Google Patents

Huperzin a analoge verbindungen

Info

Publication number
ATE219061T1
ATE219061T1 AT90904089T AT90904089T ATE219061T1 AT E219061 T1 ATE219061 T1 AT E219061T1 AT 90904089 T AT90904089 T AT 90904089T AT 90904089 T AT90904089 T AT 90904089T AT E219061 T1 ATE219061 T1 AT E219061T1
Authority
AT
Austria
Prior art keywords
huperzine
analogue compounds
medicament
analogue
compounds
Prior art date
Application number
AT90904089T
Other languages
English (en)
Inventor
Alain P Kozikowski
Yan Xia
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE219061T1 publication Critical patent/ATE219061T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT90904089T 1989-02-21 1990-02-21 Huperzin a analoge verbindungen ATE219061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/313,118 US4929731A (en) 1989-02-21 1989-02-21 Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
PCT/US1990/000925 WO1990009993A2 (en) 1989-02-21 1990-02-21 Method for the synthesis of huperzine a and analogs thereof and compounds useful therein

Publications (1)

Publication Number Publication Date
ATE219061T1 true ATE219061T1 (de) 2002-06-15

Family

ID=23214460

Family Applications (3)

Application Number Title Priority Date Filing Date
AT00201492T ATE330943T1 (de) 1989-02-21 1990-02-21 Herstellungsverfahren von huperzine a und deren analogen und verbindungen nützlich dazu
AT90904089T ATE219061T1 (de) 1989-02-21 1990-02-21 Huperzin a analoge verbindungen
AT01203687T ATE239709T1 (de) 1989-02-21 1990-02-21 Racemisches huperzin a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT00201492T ATE330943T1 (de) 1989-02-21 1990-02-21 Herstellungsverfahren von huperzine a und deren analogen und verbindungen nützlich dazu

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01203687T ATE239709T1 (de) 1989-02-21 1990-02-21 Racemisches huperzin a

Country Status (9)

Country Link
US (1) US4929731A (de)
EP (3) EP0460062B1 (de)
JP (1) JP2933386B2 (de)
AT (3) ATE330943T1 (de)
CA (2) CA2296915A1 (de)
DE (3) DE69034226T2 (de)
DK (2) DK1167354T3 (de)
ES (2) ES2173858T3 (de)
WO (1) WO1990009993A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177082A (en) * 1985-11-05 1993-01-05 Yu Chao Mei Huperzines and analogs
US5104880A (en) * 1991-05-01 1992-04-14 Mayo Foundation For Medical Education And Research Huperzine a analogs as acetylcholinesterase inhibitors
US5206393A (en) * 1991-09-30 1993-04-27 Union Carbide Chemicals & Plastics Technology Corporation Oxa-bicyclic polyfunctional compounds and preparation thereof
US5145973A (en) * 1991-09-30 1992-09-08 Union Carbide Chemicals & Plastics Technology Corporation Oxa-Bicyclic polyfunctional compounds and preparation thereof
US5547960A (en) * 1994-09-07 1996-08-20 Mayo Foundation For Medical Education And Research C-10 analogs of huperzine a
USRE38460E1 (en) 1994-12-28 2004-03-09 Shanghai Institute Of Materia Medica Chinese Academy Of Sciences Huperzine A derivatives, their preparation and their use
CN1125725A (zh) * 1994-12-28 1996-07-03 中国科学院上海药物研究所 一类海克林碱衍生物及它的用途
US6524616B1 (en) * 1999-06-25 2003-02-25 Wake Forest University Health Services Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
US6271379B1 (en) 2000-03-08 2001-08-07 Georgetown University Intermediates useful for the synthesis of huperzine A
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
US6369052B1 (en) 2000-08-07 2002-04-09 Georgetown University Combination of huperzine and nicotinic compounds as a neuroprotective agent
KR100390777B1 (ko) * 2000-12-19 2003-07-10 한국화학연구원 피리돈 유도체의 제조방법
US6967206B2 (en) 2002-12-05 2005-11-22 Access Business Group International Llc Compositions and methods for increasing growth hormone levels
US20060264455A1 (en) * 2005-05-23 2006-11-23 Schachter Steven C Use of huperzine for disorders
US8097726B2 (en) * 2006-05-17 2012-01-17 Industrial Technology Research Institute Huperzine a compound for treatment of alzheimer's disease
WO2009120774A2 (en) * 2008-03-25 2009-10-01 Debiopharm S.A. Method of preparing huperzine a and derivatives thereof
WO2010028134A2 (en) * 2008-09-04 2010-03-11 President And Fellows Of Harvard College Treatment of neurological disorders using huperzine
CN104496998B (zh) * 2014-12-15 2017-07-11 陕西嘉禾生物科技股份有限公司 一种1′‑苄基‑2′‑酮‑5′，7′，8′‑三氢‑螺‑[1，3‑二氧五环‑2]‑喹啉的制备方法
CN104496900A (zh) * 2014-12-15 2015-04-08 陕西嘉禾植物化工有限责任公司 一种2-甲氧基-6-酮-5,7,8-三氢-喹啉的制备方法
CN109705038B (zh) * 2017-10-25 2020-11-03 广州市朗启医药科技有限责任公司 石杉碱甲的合成方法
CN114716449B (zh) * 2022-04-12 2023-09-29 浙江工业大学 一种2-甲氧基-6-乙二醇缩酮-5,7,8-三氢喹啉的制备方法
CN119431243B (zh) * 2025-01-09 2025-06-10 万邦德制药集团有限公司 一种氘代石杉碱甲化合物或其药学上可接受的盐及其制备方法和应用

Also Published As

Publication number Publication date
CA2047744A1 (en) 1990-08-22
ATE239709T1 (de) 2003-05-15
ES2173858T3 (es) 2002-11-01
DE69033970T2 (de) 2002-10-02
US4929731A (en) 1990-05-29
EP0460062B1 (de) 2002-06-12
EP0460062A4 (en) 1992-07-01
EP0460062A1 (de) 1991-12-11
CA2047744C (en) 2000-05-02
WO1990009993A2 (en) 1990-09-07
DE69034226D1 (de) 2006-08-03
WO1990009993A3 (en) 1990-11-01
DK0460062T3 (da) 2002-08-26
EP1167354A2 (de) 2002-01-02
EP1167354B1 (de) 2003-05-07
DE69034226T2 (de) 2007-06-21
JP2933386B2 (ja) 1999-08-09
ES2194003T3 (es) 2003-11-16
DE69034070T2 (de) 2003-12-18
EP1026157A2 (de) 2000-08-09
CA2296915A1 (en) 1990-08-22
EP1167354A3 (de) 2002-01-09
DK1167354T3 (da) 2003-09-01
HK1030604A1 (en) 2001-05-11
DE69033970D1 (de) 2002-07-18
EP1026157A3 (de) 2004-08-11
EP1026157B1 (de) 2006-06-21
ATE330943T1 (de) 2006-07-15
DE69034070D1 (de) 2003-06-12

Similar Documents

Publication Publication Date Title
ATE219061T1 (de) Huperzin a analoge verbindungen
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
NO971889L (no) Forbindelser og sammensetninger for levering av aktive midler
EE02962B1 (et) Mometasoonfuroaadi monohüdraat, selle valmistamismeetod ja farmatseutilised kompositsioonid
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DE50015623D1 (de) Kovalent verbrückte insulindimere
SE9504661D0 (sv) New compounds
ATE255589T1 (de) Kristallin form i von clarithromycin
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
SE9201628D0 (sv) Pharmaceutical composition
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
MD2196B2 (ro) Criptoficine, procedeu de obţinere, compoziţii farmaceutice pe baza acestora, metodă de inhibare a proliferării celulelor mamiferelor şi metodă de atenuare a stării patologice cauzate de hiperproliferarea celulelor mamiferelor
GB9907571D0 (en) Compounds
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DK0701449T3 (da) Fremgangsmåde til fremstilling af en oral fast dosisform indeholdende diclofenac
SE9504662D0 (sv) New compounds
LV10917A (lv) Bambuterina pielietojums lipidu saturu pazeminosu farmaceitisku kompoziciju pagatavosanai
YU2394A (sh) Lizin so 6-hloro-5-fluoro-3-(-2-tenoil)-2-oksindol-1-karboksamida
ATE224716T1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
MX9203359A (es) Nuevas composiciones farmaceuticas de insulina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee